Abstract: SA-PO0814
Kidney Outcomes in Patients with Systemic Lupus Erythematosus (SLE) Receiving Anifrolumab in the ASTER Real-World Study
Session Information
- Glomerular Diseases: Management, Evolving Strategies, and Practice-Changing Advances
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Weinmann-Menke, Julia, Medical Center of the Johannes Gutenberg University, Mainz, Germany
- Parodis, Ioannis, Karolinska Institutet, Solna, Sweden
- Mosca, Marta, University of Pisa, Pisa, Italy
- Amoura, Zahir, Pitié-Salpêtrière Hospital, Paris, France
- Matsos, Mark, McMaster University Medical Center, Hamilton, Ontario, Canada
- Bell, John, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
- Atefi, Gelareh, BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware, United States
- Natman, Jonatan, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
- Karimi, Parisa, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, United States
- Agustin, Lyra, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
Background
Up to 30–60% of patients with SLE develop LN, which causes a range of renal outcomes from proteinuria to ESRD. Anifrolumab is approved to treat patients with SLE. Post hoc analyses of SLE trials suggest renal benefit of anifrolumab among patients with renal involvement but, to date, no studies have assessed renal outcomes with real-world anifrolumab use. We assessed renal outcomes in adults with SLE without severe active LN who received anifrolumab in routine practice as part of the ongoing, multinational, observational ASTER (NCT05637112) study.
Methods
Adults with SLE receiving standard therapy were enrolled during routine clinical visits prior to anifrolumab initiation. This 12M interim analysis reports SLE Disease Activity Index (SLEDAI) renal domain involvement in patients with non-missing data at pretreatment (PT, the most recent assessment prior to anifrolumab initiation) and 12M, and eGFR and UPCR in patients assessed at both visits.
Results
Of 255 patients, 206 (80.8%) remained on-treatment at data cut-off. Overall, 7.6% (19/251) of patients had PT SLEDAI renal involvement; the most frequent components were proteinuria and hematuria, with pyuria and urinary casts less common—typical of mild renal activity (Table). The proportion with renal involvement decreased to 3.2% (6/188) by 12M, as did proportions with proteinuria, hematuria, or pyuria. Among patients with PT renal activity who were evaluable for change (n=14), 10 (71.4%) had lower renal scores at 12M vs PT. Median eGFR and UPCR remained within normal ranges and were stable over time (Figures). Proportions of patients with UPCR ≥0.5/≥0.2–<0.5 mg/mg decreased from PT to 12M (≥0.5 mg/mg: 13.6% [3/22] vs 9.1% [2/22]; ≥0.2–<0.5 mg/mg: 18.2% [4/22] vs 13.6% [3/22]).
Conclusion
Among adults with SLE without severe active LN receiving anifrolumab in routine practice, prevalence of SLEDAI renal activity approximately halved over 12M; most patients with renal involvement experienced improvement. eGFR and UPCR remained in normal ranges and were preserved over 12M. These findings, while based on small numbers, suggest disease control with anifrolumab extends to renal manifestations in real-world care.
Acknowledgment
Medical writing by Rosie Butler, PhD, of JK Associates Inc., part of Avalere Health; this support was funded by AstraZeneca.
Funding
- Commercial Support – The study and medical writing support were funded by AstraZeneca.